The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

被引:9
作者
Al-Ziftawi, Nour Hisham [1 ]
Elazzazy, Shereen [2 ]
Alam, Mohammed Fasihul [3 ]
Shafie, Asrul [4 ]
Hamad, Anas [2 ,5 ]
Bbujassoum, Salha [6 ]
Ibrahim, Mohamed Izham Mohamed [5 ]
机构
[1] Aman Hosp, Dept Pharm, Doha, Qatar
[2] Hamad Med Corp, Natl Ctr Canc Care & Res, Pharm Dept, Doha, Qatar
[3] Qatar Univ, Coll Hlth Sci, Dept Publ Hlth, QU Hlth, Doha, Qatar
[4] Univ Sains Malaysia, Sch Pharmaceut Sci, Gelugor, Malaysia
[5] Qatar Univ, Coll Pharm, QU Hlth, Doha, Qatar
[6] Hamad Med Corp, Natl Ctr Canc Care & Res, Med Oncol Dept, Doha, Qatar
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
cyclin-dependent-kinase; 4/6; inhibitors; HR+/HER-2 negative; advanced breast cancer (ABC); effectiveness & efficiency (E&E); CDK4/6 cell cycle inhibitors; PLUS FULVESTRANT; ABEMACICLIB; LETROZOLE; THERAPY; COMBINATION; INHIBITOR; SURVIVAL; WOMEN;
D O I
10.3389/fonc.2023.1203684
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Palbociclib and ribociclib are indicated in the first-line treatment of hormonal receptor-positive HER-2 negative (HR+/HER2- negative) advanced breast cancer. Although randomized-controlled trials (RCTs) proved their clinical efficacy, there are no observational studies yet to validate the clinical findings in the real-world. Therefore, this study aimed to evaluate and compare the clinical effectiveness and safety profiles of palbociclib and ribociclib in Qatar.Materials and methods: A retrospective observational study was conducted on HR+/HER-2-negative stage-IV breast cancer patients receiving palbociclib or ribociclib in the state of Qatar. Clinical data were collected from the National Center for Cancer Care and Research (NCCCR) in Qatar using Cerner (R). Primary outcomes were progression-free-survival (PFS) and overall-survival (OS) generated by Kaplan-Meier curves. Moreover, safety profiles of both two treatments were evaluated.Results: The data from 108 patients were included in the final analysis. There was no statistically significant difference in PFS between the palbociclib and ribociclib groups; PFS was 17.85 versus 13.55 months, respectively(p> 0.05). Similarly, there was no statistically significant difference in OS between the two medications, 29.82 versus 31.72 months, respectively(p>0.05). Adverse events were similar between the two groups. Neutropenia was the most common side effect in the study population accounting for 59.3% of the patients.Conclusions: Therefore, both treatments have similar efficacy and safety profiles. Further research on a larger-scale population and longer follow-up period is recommeneded.
引用
收藏
页数:13
相关论文
共 49 条
[1]   Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation [J].
Al-Ziftawi, Nour Hisham ;
Alam, Mohammed Fasihul ;
Elazzazy, Shereen ;
Shafie, Asrul Akmal ;
Hamad, Anas ;
Ibrahim, Mohamed Izham Mohamed .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2023, 20 (01)
[2]  
American Cancer Society, SURVIVAL RATES BREAS
[3]  
[Anonymous], 2020, Female Breast Cancer Subtypes - Cancer Stat Facts. Surveillance, Epidemiology
[4]  
[Anonymous], 2018, Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018
[5]  
[Anonymous], SPSS STAT
[6]  
[Anonymous], 2020, CANC FACTS FIGURES 2
[7]  
[Anonymous], 2020, Treating Breast Cancer
[8]   Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making [J].
Berger, Marc L. ;
Sox, Harold ;
Willke, Richard J. ;
Brixner, Diana L. ;
Eichler, Hans-Georg ;
Goettsch, Wim ;
Madigan, David ;
Makady, Amr ;
Schneeweiss, Sebastian ;
Tarricone, Rosanna ;
Wang, Shirley V. ;
Watkins, John ;
Daniel Mullins, C. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) :1033-1039
[9]  
Breast Cancer.org, 2023, IHC (ImmunoHistoChemistry) Tests
[10]   A rapid rise in hormone receptor-positive and HER2-positive breast cancer subtypes in Southern Thai women: A population-based study in Songkhla [J].
Chuaychai, Aungkana ;
Sriplung, Hutcha .
PLOS ONE, 2022, 17 (03)